EXHIBIT 99.1

FOR IMMEDIATE RELEASE

Investor Contacts:
Richard T. Schumacher, President & CEO                Pressure BioSciences, Inc.
R. Wayne Fritzsche, Chairman                                  (508) 580-1818 (T)

              PRESSURE BIOSCIENCES, INC. PROVIDES CORPORATE UPDATE


West Bridgewater, MA, April 3, 2006 - Pressure BioSciences, Inc. (NASDAQ: PBIO)
today provided an update on corporate activities of the past several months,
including the announcement of two additions and one promotion to its senior
management staff.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "We are pleased
to announce that Mr. Edward H. Myles has been hired as our new Vice President of
Finance and Chief Financial Officer; Dr. Nathan P. Lawrence has been promoted to
the newly created position of Vice President of Marketing and Business
Development; and Dr. Alexander V. Lazarev has been hired as Director of Research
and Development, a position that became vacant following the promotion of Dr.
Lawrence."

Mr. Schumacher continued: "In addition to these important senior management
changes, several additional events have occurred over the past several months
that have served to strengthen our balance sheet and help solidify the overall
health of our company, specifically: (1) we have received the remaining escrow
funds from the SeraCare transaction (approximately $1.1 million); (2) we have
received approximately $518,000 from the sale of 57,900 shares of Panacos
Pharmaceuticals; (3) we have secured state-of-the-art laboratory space for our
R&D activities in Woburn Massachusetts; (4) we have begun working with
collaborators who are recognized experts in the areas of forensics,
anti-bioterrorism, and agriculture; and (5) we have reported financial results
in our Form-10KSB that were in line with internal expectations. As a company, we
look forward to the future with excitement and anticipation."

About Mr. Edward H. Myles

Mr. Myles has more than 12 years of finance and accounting experience, most
recently as Controller for EMD Pharmaceuticals, a wholly-owned affiliate of
Merck KGaA. Prior to EMD, Mr. Myles held various financial positions at SG Cowen
Securities Corporation, Boston Biomedica, and PricewaterhouseCoopers. Mr. Myles
became a CPA in 1996, and earned a B.S.B.A. in accounting and finance from the
University of Hartford and an MBA from Washington University in St. Louis.

About Dr. Nathan P. Lawrence

Dr. Lawrence was Director of Research and Development at Pressure BioSciences
prior to his promotion to Vice President of Marketing and Business Development.
Prior to PBI, Dr. Lawrence held various scientific positions at 454 Life
Sciences, Boston Biomedica, Becton Dickinson, and Gene-Trak Systems. Dr.
Lawrence earned his B.A. at the University of Miami, his M.S. at Southern
Connecticut State University, and his Ph.D. at Yale University.

                                       8


About Dr. Alexander V. Lazarev

Dr. Lazarev was most recently Director of New Technology Development at Proteome
Systems, Inc. (PSI). Prior to PSI, Dr. Lazarev held various scientific positions
at Genomic Solutions, Inc., PhytoChem Technologies, Inc., Ohio State University
School of Medicine, and the Uniformed Services University of Health Sciences.
Dr. Lazarev earned his undergraduate and graduate degrees at the University of
Kazan, Russian Federation.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company
focused on the development of a novel technology called Pressure Cycling
Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and
ultra-high levels (up to 35,000 psi and greater) to control bio-molecular
interactions. PBI currently holds 13 US and 4 foreign patents covering multiple
applications of PCT in the life sciences field, including in such areas as
genomic and proteomic sample preparation, pathogen inactivation, the control of
enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions,
hopes, beliefs, expectations or predictions of the future are "forward-looking''
statements within the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the Company's expectations about the
future. These statements are based upon the Company's current expectations,
forecasts, and assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ materially from
those indicated by these forward-looking statements. These risks, uncertainties,
and other factors include, but are not limited to: fluctuations in the Company's
financial and operating results, which could adversely affect the Company's cash
flow; uncertainties inherent in the development of new products, including the
Company's new Bench Top PCT instrument, including technical risks, cost
overruns, and manufacturing and other delays; the risk that newly introduced
products may contain undetected errors or defects or otherwise not perform as
anticipated; the risk that the Company's products will not achieve market
acceptance; the risk that the Company will not be able to increase demand or
sales for its products; the risk that the Company will face adverse changes in
the Company's liquidity and capital resources; the risk that the Company will be
unable to attract and retain qualified personnel; the risk that the hiring of
Mr. Myles and Dr. Lazarev and the promotion of Dr. Lawrence may not benefit the
Company; declines in the market price of the Company's common stock; declines in
the market price of Panacos Pharmaceuticals common stock; the risk that the
Company's shares of Panacos Pharmaceuticals common stock held in escrow may not
be released to the Company in September 2006; the risk that loans from the
Company may not be repaid; changes in the capital markets; competition; general
and industry-specific economic conditions; and the other risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual Report on
Form 10-KSB for the year ended December 31, 2005 and other reports filed by the
Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise
required by law.


           Visit us at our website http://www.pressurebiosciences.com

                                       9